Cysview® (hexaminolevulinate hydrochloride) is indicated as an adjunct to white-light cystoscopy in the detection of non-muscle invasive papillary bladder cancer, in patients with known or suspicion of bladder cancer.

Click here for Part III: Consumer Information of the Product Monograph

Ask your doctor or hospital about new tools to help detect
non-muscle invasive papillary bladder cancer. Ask your doctor if you are a suitable patient.

Hospitals Using Cysview®

  • Princess Margaret Cancer Centre (Toronto, ON)
  • Brockville General Hospital (Brockville, ON)
  • Humber River Hospital (Toronto, ON)
  • Kingston General Hospital (Kingston, ON)
  • Vancouver General Hospital (Vancouver, BC)
  • University of British Columbia (Vancouver, BC)
  • Surrey Memorial Hospital (Surrey, BC)
  • Jim Pattison Outpatient Care and Surgery Centre (Surrey, BC)
  • Toronto General Hospital (Toronto, ON)

Check this page regularly for updates

Hospitals in the Process of Evaluating/Considering Cysview®

  • Victoria General Hospital (Victoria, BC)
  • Health Sciences North (Sudbury, ON)
  • Centre universitaire de sante McGill (CUSM) - Glen Site (Montreal, QC)
  • University of Alberta (Edmonton, AB)
  • Jewish General Hospital (Montreal, QC)
  • London Health Sciences Centre (London, ON)

In The News

Jan 20, 2017 -

March 24, 2017 - KGH Connect

April 5, 2017 -

Nov 20, 2017 -

Jan 25, 2018 -

Mar 15, 2018 -

Jun 1, 2018 - Vancouver Sun

Nov 9, 2018 - As seen in MacLean's Magazine - Personal Health News

Dec 22, 2018 - As seen in the Toronto Star - Personal Health News

Jan 10, 2019 -